Evidence map›Paper›PMID 41970685›Full record

ArticleEndoscopy international open2026

Uncovered versus fully-covered self-expandable metal stents for nonpancreatic cancer: Propensity score-matched, multicenter study.

Fumitaka Niiya, Tatsunori Satoh, Junichi Kaneko, Kazuma Ishikawa, Naoki Tamai, Masataka Yamawaki, Jun Noda, Tetsushi Azami, Yuichi Takano, Masatsugu Nagahama

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endoscopy international open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Fumitaka NiiyaDivision of Gastroenterology, Department of Internal Medicine, Showa Medical University Fujigaoka Hospital, Yokohama, Japan.ORCID 0000-0002-2248-8655
Tatsunori SatohDepartment of Gastroenterology, Shizuoka General Hospital, Shizuoka, Japan.ORCID 0000-0002-1756-3147
Junichi KanekoDepartment of Gastroenterology, Iwata City Hospital, Iwata, Japan.
Kazuma IshikawaOncology, Sapporo Ika Daigaku, Sapporo, Japan.
Naoki TamaiDivision of Gastroenterology, Department of Internal Medicine, Showa Medical University Fujigaoka Hospital, Yokohama, Japan.
Masataka YamawakiDivision of Gastroenterology, Department of Internal Medicine, Showa Medical University Fujigaoka Hospital, Yokohama, Japan.
Jun NodaDivision of Gastroenterology, Department of Internal Medicine, Showa Medical University Fujigaoka Hospital, Yokohama, Japan.ORCID 0009-0006-1254-9246
Tetsushi AzamiDivision of Gastroenterology, Department of Internal Medicine, Showa Medical University Fujigaoka Hospital, Yokohama, Japan.
Yuichi TakanoDivision of Gastroenterology, Department of Internal Medicine, Showa Medical University Fujigaoka Hospital, Yokohama, Japan.ORCID 0000-0001-6803-9460
Masatsugu NagahamaDivision of Gastroenterology, Department of Internal Medicine, Showa Medical University Fujigaoka Hospital, Yokohama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and study aims: The efficacy of uncovered self-expandable metal stents (UCSEMS) compared to that of fully covered self-expandable metal stents (FCSEMS) for distal malignant biliary obstruction (dMBO) is controversial. Studies have highlighted the heterogeneity of disease conditions because pancreatic and nonpancreatic cancers exhibit different clinical courses. This is the first study to specifically compare the safety and efficacy of UCSEMS and FCSEMS for dMBO caused by nonpancreatic cancer. Patients and methods: This retrospective multicenter study included patients who underwent UCSEMS or FCSEMS placement for nonpancreatic cancer-induced dMBO at four centers between January 2010 and April 2024. Propensity score matching (PSM) (1:1) of both groups was performed. Technical and clinical success, adverse events, recurrent biliary obstruction (RBO), time to RBO (TRBO), and overall survival (OS) of these groups were compared. Results: After PSM, 24 patients were included in each group. Technical and clinical success rates and TRBO did not differ significantly between the groups (median TRBO: 311 days [UCSEMS] vs 317 days [FCSEMS]; Conclusions: UCSEMS may be safer than FCSEMS for managing dMBO caused by nonpancreatic cancer.

Indexed as

ERC topicsPancreatobiliary (ERCP/PTCD)Performance and complicationsQuality and logistical aspectsStrictures

Identifiers

PMID41970685
PMCPMC13062671

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.